SecBot SecBot
SECBOTREPLAY Home › Report › SMMT

SMMT · Summit Therapeutics reported Q1 2026 financial results and operational…

Summit Therapeutics Inc. · 8-K filed Apr 30, 2026 at 16:40 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Apr 30, 2026 at 16:40 ET

Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted a GAAP net loss of $189.4M ($0.24/share), wider than the $62.9M loss in Q1 2025, driven by increased R&D and stock-based compensation. Key catalysts include the upcoming ASCO 2026 presentation of HARMONi-6 overall survival data as a late-breaking abstract and the HARMONi-3 squamous cohort final PFS data expected in H2 2026, with the PDUFA date for ivonescimab BLA set for November 14, 2026.

  • GAAP net loss of $189.4M ($0.24/share) in Q1 2026 vs $62.9M ($0.09/share) in Q1 2025
  • Cash and short-term investments at $598.7M as of March 31, 2026, down from $713.4M at year-end 2025
  • HARMONi-6 overall survival data selected as late-breaking abstract for ASCO 2026 Plenary Session on May 31, 2026
  • HARMONi-3 squamous cohort interim PFS analysis completed; iDMC recommended study continue; final PFS data expected H2 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access